Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the dose of the GLP-1 receptor antagonist
exendin(9-39) which blocks the insulinotropic action of synthetic GLP-1 by at least 95%.
Phase:
Phase 1
Details
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Collaborators:
German Research Foundation Merck Sharp & Dohme Corp.